Trastuzumab Re-Introduction with FOLFIRI for Treatment of HER2 Overexpression-Advanced Gastric Adenocarcinoma Following Failure of Other Trastuzumab-Based Chemotherapy Regimens
作者： Olivier Dubreuil , Aziz Zaanan , Olivier Pellerin , Jean-Baptiste Bachet , Philippe Rougier
关键词:
摘要: A 67-year-old man diagnosed with HER2 overexpression advanced gastric adenocarcinoma and metastasis to liver lungs was admitted for tertiary care. He received a third line chemotherapy that consists of trastuzumab combined FOLFIRI regimen (irinotecan plus 5-FU/LV) following disease relapse after an initial successful response combination 5FU + oxaliplatin trastuzumab. The patient showed favorable prolonged it. In addition the well tolerated devoid remarkable side effects. assessed clinically through CT scan imaging upper gastrointestinal endoscopy. This case report shows firstly could be tested as another in metastatic cancer, and, secondly, this disease, like breast continuation progression under antibody order improve efficacy treatment Trastuzumab re-introduction overexpression-advanced failure other trastuzumab-based regimens.
sci-hub.st 参考文章(15)
J S Waters, A Norman, D Cunningham, J H Scarffe, A Webb, P Harper, J K Joffe, M Mackean, J Mansi, M Leahy, A Hill, J Oates, S Rao, M Nicolson, T Hickish, Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. ,vol. 80, pp. 269- 272 ,(1999) , 10.1038/SJ.BJC.6690350
Klaus Dumke, Martin Krüger, Florian Weissinger, Marc Reymond, Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T). Onkologie. ,vol. 34, pp. 548- 551 ,(2011) , 10.1159/000332226
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh, Giuseppe Aprile, Evgeny Kulikov, Julie Hill, Michaela Lehle, Josef Rüschoff, Yoon-Koo Kang, None, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial The Lancet. ,vol. 376, pp. 687- 697 ,(2010) , 10.1016/S0140-6736(10)61121-X
Jean‐Marc Extra, Eric C. Antoine, Anne Vincent‐Salomon, Thierry Delozier, Pierre Kerbrat, Anne Bethune‐Volters, Jean‐Paul Guastalla, Marc Spielmann, Louis Mauriac, Jean‐Louis Misset, Daniel Serin, Mario Campone, Christophe Hebert, Céline Remblier, Loïc Bergougnoux, Frank Campana, Moïse Namer, Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study Oncologist. ,vol. 15, pp. 799- 809 ,(2010) , 10.1634/THEONCOLOGIST.2009-0029
Ahmedin Jemal, Freddie Bray, Melissa M. Center, Jacques Ferlay, Elizabeth Ward, David Forman, Global cancer statistics CA: A Cancer Journal for Clinicians. ,vol. 61, pp. 69- 90 ,(1999) , 10.3322/CAAC.20107
Salah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, Harald Schmalenberg, Stephan Hollerbach, Ralf Hofheinz, Volker Rethwisch, Gernot Seipelt, Nils Homann, Gerhard Wilhelm, Gunter Schuch, Jan Stoehlmacher, Hans Günter Derigs, Susanna Hegewisch-Becker, Johannes Grossmann, Claudia Pauligk, Akin Atmaca, Carsten Bokemeyer, Alexander Knuth, Elke Jäger, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology. ,vol. 26, pp. 1435- 1442 ,(2008) , 10.1200/JCO.2007.13.9378
Daisuke Sakai, Taroh Satoh, Yukinori Kurokawa, Toshihiro Kudo, Kazuhiro Nishikawa, Yoshio Oka, Toshimasa Tsujinaka, Toshio Shimokawa, Yuichiro Doki, Hiroshi Furukawa, A Phase II Trial of Trastuzumab Combined with Irinotecan in Patients with Advanced HER2-positive Chemo-refractory Gastric Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5) Japanese Journal of Clinical Oncology. ,vol. 43, pp. 838- 840 ,(2013) , 10.1093/JJCO/HYT083
Rosine Guimbaud, Christophe Louvet, Pauline Ries, Marc Ychou, Emilie Maillard, Thierry André, Jean-Marc Gornet, Thomas Aparicio, Suzanne Nguyen, Ahmed Azzedine, Pierre-Luc Etienne, Eveline Boucher, Christine Rebischung, Pascal Hammel, Philippe Rougier, Laurent Bedenne, Olivier Bouché, Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study Journal of Clinical Oncology. ,vol. 32, pp. 3520- 3526 ,(2014) , 10.1200/JCO.2013.54.1011
Eric Van Cutsem, Vladimir M. Moiseyenko, Sergei Tjulandin, Alejandro Majlis, Manuel Constenla, Corrado Boni, Adriano Rodrigues, Miguel Fodor, Yee Chao, Edouard Voznyi, Marie-Laure Risse, Jaffer A. Ajani, Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group Journal of Clinical Oncology. ,vol. 24, pp. 4991- 4997 ,(2006) , 10.1200/JCO.2006.06.8429
Gunter von Minckwitz, Andreas du Bois, Marcus Schmidt, Nicolai Maass, Tanja Cufer, Felix E. de Jongh, Eduard Maartense, Christoph Zielinski, Manfred Kaufmann, Wolfgang Bauer, Klaus H. Baumann, Michael R. Clemens, Ralph Duerr, Christoph Uleer, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl, Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study Journal of Clinical Oncology. ,vol. 27, pp. 1999- 2006 ,(2009) , 10.1200/JCO.2008.19.6618